Key updates at ASCO GU 2025: STAMPEDE, CheckMate 214, and more

from VJOncology Podcast · host VJOncology

Join us in this episode as we go through the latest advancements in genitourinary cancer treatment presented at ASCO GU 2025 in San Francisco. Our expert guests provide insights into ground-breaking trials and studies that are reshaping the landscape of cancer therapy. Join Nadine Houede, Xinan Sheng, Nicholas James, and Wenxin Xu, as they discuss highly anticipated updates such as results of neoadjuvant durvalumab with chemotherapy in high-risk high-risk upper tract urothelial carcinoma (UTUC), disitamab vedotin and toripalimab in HER2-expressing bladder cancer, and updates from the STAMPEDE trial.

Episode metadata supplied by the publisher feed · Published Feb 21, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Key updates at ASCO GU 2025: STAMPEDE, CheckMate 214, and more

0:00 14:49

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of VJOncology Podcast?

This episode is 14 minutes long.

When was this VJOncology Podcast episode published?

This episode was published on February 21, 2025.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this VJOncology Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!